Shares of Bionano Genomics (NASDAQ: BNGO) soared 25.13% in intraday trading on Thursday, following the company's impressive first-quarter 2025 earnings report that significantly surpassed analyst expectations. The genomics company's strong financial performance and positive future outlook have ignited investor enthusiasm, driving the stock to new heights.

Bionano Genomics reported a loss of $1.15 per share for Q1 2025, substantially outperforming the analyst consensus estimate of a $3.02 loss. This marks a remarkable improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million. Despite a 25.88% year-over-year decrease in revenue, the company highlighted an impressive gross margin of 46% for the quarter, indicating enhanced operational efficiency.

Looking ahead, Bionano Genomics provided an optimistic full-year 2025 revenue outlook, projecting between $26 million to $30 million. The company also reaffirmed its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Furthermore, Bionano reported an extended cash runway into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises. This improved financial position, combined with the strong quarterly performance and positive outlook, has bolstered investor confidence in the company's growth prospects, contributing to the significant stock price surge.